PEPFAR disruption could kill half a million children by 2030, study finds
Half a million children could die from AIDS by 2030 because of disruptions to the flagship US HIV prevention project PEPFAR, experts have warned.
Their analysis, published in The Lancet on Tuesday, estimates that one million additional children could be infected with HIV and almost half a million of them could die by the end of the decade if PEPFAR's programmes are reduced or eliminated.
On top of the infections, some 2.8 million children could be orphaned by HIV-related deaths, they found.
PEPFAR was established by George W Bush, the US President, in 2003. So far, it has saved over 26 million lives, protected 7.5 million babies and supported 10 million orphans with HIV prevention and treatment.
Since its inception, the project has put more than $120 billion (£94 bn) into efforts to tackle HIV – the largest commitment by any nation in history to address a single disease. It operates in more than 50 countries around the world.
The support PEPFAR funding provides includes life-saving antiretroviral treatments for those with HIV, as well as antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection. It also supports voluntary medical male circumcisions, the training of health care workers, and HIV prevention services for girls and young women.
On January 20, Donald Trump signed an executive order halting these life-saving efforts. The decision followed news that several nurses funded by PEPFAR had performed illegal abortions in Mozambique.
Prof Lucie Cluver, co-lead author of the analysis, from the University of Oxford, was a social worker in South Africa before PEPFAR was introduced.
'My work was with dying children and mothers and I had nothing to give them. Then PEPFAR came and everything changed – it was like seeing a continent come to life again,' she told the Telegraph.
But the suspension of PEPFAR has thrown efforts to end HIV and AIDS into jeopardy, she said.
'Losing stable, long-term support for PEPFAR programmes sets global progress to end HIV/AIDS back to the dark ages of the epidemic, especially for children and adolescents,' she said.
Prof Cluver said a colleague had recently returned from the rural Copperbelt in Zambia and told her it felt like the clock had been turned back 25 years.
'They were seeing children with sores on their faces and mothers dying again,' she said.
The impact of PEPFAR extends beyond HIV and AIDS prevention – it also also supports many programmes working to improve child health and eliminate sexual violence against girls.
If these programmes end, there is a risk that the children they help will 'slip through the cracks,' said Susan Hillis, a Senior Research Officer at Imperial College London and another of the report's co-authors.
'[Reducing] sexual violence is one of the most fundamental things PEPFAR has done,' Prof Cluver added. 'It's often how young girls are contracting HIV and those who have been victimised get mentorship, counselling and support. Losing it would be catastrophic.'
The researchers urged the US to support a five-year transition plan instead of stopping PEPFAR immediately, so that responsibility for its programmes can be taken on gradually by African governments.
'What is urgently needed now is a well-planned transition to expanded country-ownership of PEPFAR programmes that will offer stability for countries that currently rely on PEPFAR support,' said co-author Prof Chris Desmond, of the University of Kwazulu-Natal.
Prof Cluver told the Telegraph that, if PEPFAR is terminated, the country most affected will be the US itself.
'PEPFAR is so important to the way the US is viewed globally. It is the reason why the US has such strong trade and diplomatic relations with Africa. I hope they'll make the right choice.'
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
6 hours ago
- Business Wire
Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the closing of a $66 million Series B financing. New investor Regeneron Ventures and current investor Deerfield Management co-led the financing, with participation from existing investors Canaan, Droia Ventures and Euclidean Capital. Actio's pipeline is led by ABS-1230, a KCNT1 inhibitor for the treatment of KCNT1-related epilepsy and other genetic epilepsies, and ABS-0871, a TRPV4 inhibitor currently being evaluated in a Phase 1 healthy volunteer clinical trial for the treatment of Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder. 'We have made tremendous progress across our pipeline – executing a precision medicine strategy that targets the root causes of disease through genetically informed drug development,' said David Goldstein, Ph.D., co-founder and CEO of Actio. 'ABS-1230 and ABS-0871 have the potential to be transformative disease-modifying therapies in their respective rare indications and growing evidence supports expansion into broader indications. This new funding from industry-leading investors speaks to the value of our approach and provides us with important resources to continue advancing our programs.' The Series B financing will support the advancement of Actio's lead programs, ABS-1230 and ABS-0871. ABS-1230 is a potential first-in-class oral, selective small molecule KCNT1 inhibitor for the treatment of KCNT1-related epilepsy, a rare and often fatal pediatric epileptic encephalopathy with a United States (U.S.) prevalence of approximately 2,500 individuals. In preclinical studies, ABS-1230 has been shown to inhibit all recurrently observed pathogenic mutations in the KCNT1 gene, making ABS-1230 broadly applicable to patients with KCNT1-positive epilepsy. Actio plans to initiate the healthy volunteer portion of a Phase 1 clinical trial of ABS-1230 in the second half of 2025 with plans to expand into a proof-of-concept Phase 1b study in KCNT1-related epilepsy patients in early 2026. ABS-1230 was recently granted both rare pediatric and orphan drug designations from the U.S. Food and Drug Administration (FDA). ABS-0871 is a potential first-in-class oral, small molecule TRPV4 inhibitor for the treatment of CMT2C, a rare inherited disorder that affects both motor and sensory functions with a U.S. prevalence of approximately 2,500 individuals. Preclinical evaluation of this program in novel construct valid CMT2C rare disease models has demonstrated marked improvements in motor function and mobility, compared to untreated controls. Given its mechanism of action targeting TRPV4, ABS-0871 may also have therapeutic potential for the treatment of overactive bladder. Actio is currently advancing ABS-0871 in the healthy volunteer portion of a Phase 1 clinical trial with plans to expand into a Phase 1b study in patients with TRPV4+ CMT2C in 2026. ABS-0871 was granted rare pediatric drug, orphan drug and fast track designations from the FDA. 'Actio has done an exceptional job of identifying serious unmet needs in rare disease and advancing solutions that may also be applicable to patients with more common diseases,' said Jason Fuller, Ph.D., Partner, Deerfield Management. 'We're pleased to support the company, encouraged by its progress, and excited by the team's potential to make a difference for patients.' About Actio Biosciences Actio Biosciences is a clinical-stage company leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Actio is advancing two lead rare disease programs – ABS-0871 and ABS-1230 – with first-in-class potential for the treatment of Charcot-Marie-Tooth disease, type 2C (CMT2C) and KCNT1-related epilepsy, respectively. Founded in October 2021, the San Diego-based company is guided by leaders in genetics and drug development and backed by top healthcare investors. For more information, please visit and follow the company on LinkedIn and X.

Associated Press
6 hours ago
- Associated Press
Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success
Thailand's National Innovation—Mangosteen-Based Immunotherapy Fights HIV/AIDS Bangkok, Thailand, June 18, 2025 -- The Operation BIM research team from Asian Phytoceuticals Public Company Limited, led by Professor Dr. Pichaet Wiriyachitra, has announced a significant achievement in immunotherapy innovation using Fortified Mangosteen Extracts. This natural formulation has helped 80 individuals living with HIV/AIDS reach a state known as 'ByeByeHIV', characterized by strong health and, in some cases, the complete eradication of the virus from their bodies. The study has been published in the international journal Clinical Immunology Research under the title 'ByeByeHIV with Thai Innovation.' According to the Ministry of Public Health, in 2025, Thailand is projected to have 8,862 new HIV cases,10,217 people have died from AIDS-related conditions, while 568,565 individuals are living with HIV. ' ByeByeHIV ' refers to a condition where HIV/AIDS patients can reduce their viral load to undetectable levels without the use of antiretroviral drugs (ARVs) while maintaining good health. It also applies to those who had adverse side effects from ARVs and can now discontinue treatment while staying healthy and HIV-undetectable. The ByeByeHIV innovation is based on a natural extract formula composed of mangosteen, black sesame, soy, guava, and Centella asiatica. This dietary supplement, approved by the Thai FDA, boosts immune functions—especially Th1, Th17, and Killer T cells—targeting infected cells and repairing HIV- and ARV-induced telomere damage. Based on the February 2024 publication titled 'ByeByeHIV with Thai Innovation', ByeByeHIV with Thai Innovation: the formula successfully helped two groups: · Group A: 24 HIV-positive individuals never on ARVs · Group B: 26 individuals previously treated with ARVs By December 2024, both groups expanded to 40 participants each, all of whom achieved ByeByeHIV. The latest journal article, ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Caseswithout the Use of ARV Drugs (Group A), reports all 40 participants in Group A achieved ByeByeHIV. Notably, 15 individuals stopped the mangosteen-based regimen for 6 months to over 4 years while maintaining undetectable viral loads and excellent health. The first participant to discontinue the formula has now been virus-free for nearly 10 years., This suggests complete HIV eradication for the 15 individuals. The Group B study (Progress Update on 40 Cases with Prior Use of ARV Drugs) shows that all 40 participants also reached ByeByeHIV, with 15 discontinuing the regimen for 3 months to over 2 years—remaining healthy and HIV-free. This implies HIV/AIDS may now be curable without relapse. ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A) ByeByeHIV with Plant-Based Immunotherapy : Progress Update on 40 Cases with Prior Use of ARV Drugs (Group B) These three remarkable recoveries highlight the potential of natural extract-based innovations in HIV treatment—restoring life quality to normalcy. All three individuals have publicly come forward and now serve as mentors, inspiring others to overcome stigma and reclaim their lives. Professor Dr. Pichaet summarized 'This study confirms the potential of ByeByeHIV formula as a viable alternative for HIV patients unable to tolerate ARVs or new patients avoiding long-term ARV use. This marks a historic milestone for Thailand—challenging the 40-year belief that HIV/AIDS cannot be cured.' 'This Thai national innovation deserves global recognition for safely awakening the body natural healing power without side effects. Though categorized as a supplement, it has achieved what pharmaceuticals could not. Legal frameworks should evolve to reflect modern scientific breakthroughs.' Contact Info: Name: APCO Bangkok Office Email: Send Email Organization: Asian Phytoceuticals Public Company Limited Address: 30th Floor, AIA Capital Center, 89 Ratchadaphisek Road, Dindaeng District, Bangkok 10400, Thailand Phone: 0-2646-4800 Website: Release ID: 89162203 If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
Yahoo
7 hours ago
- Yahoo
Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success
Thailand's National Innovation-Mangosteen-Based Immunotherapy Fights HIV/AIDS Bangkok, Thailand--(Newsfile Corp. - June 18, 2025) - The Operation BIM research team from Asian Phytoceuticals Public Company Limited, led by Professor Dr. Pichaet Wiriyachitra, has announced a significant achievement in immunotherapy innovation using Fortified Mangosteen Extracts. This natural formulation has helped 80 individuals living with HIV/AIDS reach a state known as "ByeByeHIV", characterized by strong health and, in some cases, the complete eradication of the virus from their bodies. The study has been published in the international journal Clinical Immunology Research under the title "ByeByeHIV with Thai Innovation." Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success To view an enhanced version of this graphic, please visit: According to the Ministry of Public Health, in 2025, Thailand is projected to have 8,862 new HIV cases, 10,217 people have died from AIDS-related conditions, while 568,565 individuals are living with HIV. "ByeByeHIV" refers to a condition where HIV/AIDS patients can reduce their viral load to undetectable levels without the use of antiretroviral drugs (ARVs) while maintaining good health. It also applies to those who had adverse side effects from ARVs and can now discontinue treatment while staying healthy and HIV-undetectable. The ByeByeHIV innovation is based on a natural extract formula composed of mangosteen, black sesame, soy, guava, and Centella asiatica. This dietary supplement, approved by the Thai FDA, boosts immune functions—especially Th1, Th17, and Killer T cells—targeting infected cells and repairing HIV- and ARV-induced telomere damage. Based on the February 2024 publication titled "ByeByeHIV with Thai Innovation", (ByeByeHIV with Thai Innovation: the formula successfully helped two groups: Group A: 24 HIV-positive individuals never on ARVs Group B: 26 individuals previously treated with ARVs By December 2024, both groups expanded to 40 participants each, all of whom achieved ByeByeHIV. The latest journal article, ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A), reports all 40 participants in Group A achieved ByeByeHIV. Notably, 15 individuals stopped the mangosteen-based regimen for 6 months to over 4 years while maintaining undetectable viral loads and excellent health. The first participant to discontinue the formula has now been virus-free for nearly 10 years. This suggests complete HIV eradication for the 15 individuals. The Group B study (Progress Update on 40 Cases with Prior Use of ARV Drugs) shows that all 40 participants also reached ByeByeHIV, with 15 discontinuing the regimen for 3 months to over 2 years—remaining healthy and HIV-free. This implies HIV/AIDS may now be curable without relapse. ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A) ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases with Prior Use of ARV Drugs (Group B) These three remarkable recoveries highlight the potential of natural extract-based innovations in HIV treatment—restoring life quality to normalcy. All three individuals have publicly come forward and now serve as mentors, inspiring others to overcome stigma and reclaim their lives. Professor Dr. Pichaet summarized, "This study confirms the potential of ByeByeHIV formula as a viable alternative for HIV patients unable to tolerate ARVs or new patients avoiding long-term ARV use. This marks a historic milestone for Thailand—challenging the 40-year belief that HIV/AIDS cannot be cured." "This Thai national innovation deserves global recognition for safely awakening the body natural healing power without side effects. Though categorized as a supplement, it has achieved what pharmaceuticals could not. Legal frameworks should evolve to reflect modern scientific breakthroughs." Contact Info:Name: APCO Bangkok OfficeEmail: apco@ Asian Phytoceuticals Public Company LimitedAddress: 30th Floor, AIA Capital Center, 89 Ratchadaphisek Road, Dindaeng District, Bangkok 10400, ThailandPhone: 0-2646-4800Website: To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data